FDA Clears AI-Powered MRI Software for ARIA Detection in Patients with Alzheimer’s Disease
Icobrain.aria is reportedly the first AI software geared toward the detection and monitoring of amyloid-related imaging abnormalities (ARIAs) on brain MRI.
The Food and Drug Administration (FDA) has granted 510(k) clearance for icobrain.aria, an artificial intelligence (AI)-enabled software that may enhance the detection of amyloid-related imaging abnormalities (ARIAs) on brain MRI for patients being treated for Alzheimer’s disease.
Noting that ARIAs have been associated with recently approved disease-modifying agents for Alzheimer’s disease, Icometrix, the developer of icobrain.aria, said icobrain.aria is the first AI software dedicated to the diagnosis and monitoring of ARIAs in this patient population.
The images above reveal severe ARIA-E in a patient who presented with parenchymal edema. The AI-enabled software icobrain.aria, which was recently cleared by the FDA, demonstrated a 16 percent increase in sensitivity for ARIA-E and a 10 percent increase in sensitivity for ARIA-H, in a retrospective study published earlier this year in JAMA Network Open. (Images courtesy of JAMA Network Open.)
In a retrospective study published earlier this year in JAMA Network Open, icobrain.aria demonstrated a 16 percent increase in sensitivity for ARIA-E and a 10 percent increase in sensitivity for ARIA-H.
“New standardized tools are needed … to assist radiologists and treating clinicians in detecting and managing ARIA to optimize patient safety. I am excited that icobrain.aria has received FDA approval, clearing the way for wider use in clinical practice,” noted Stephen Salloway, M.D., the director of neurology and the Memory and Aging Program at Butler Hospital in Providence, R.I.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 4th 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 4th 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
